PDF(Pubmed)
Abstract：
The novel coronavirus pandemic has taken a toll on the global healthcare systems and economy. Safety precautions, along with vaccination, are the most effective preventive measures. The global vaccination program against COVID-19 has dramatically reduced the number of deaths and cases. However, the incidence of thrombotic events and thrombocytopenia post-COVID-19 vaccination known as vaccine-induced thrombotic thrombocytopenia has raised safety concerns. This has led to an element of vaccine hesitancy. The exact mechanism for vaccine-induced thrombotic thrombocytopenia is unknown. Although the incidence of thrombosis associated with COVID-19 vaccination is low, it still requires attention, especially in older people, smokers, and people with preexisting comorbidities. This study aims to review the pathophysiology, diagnosis, and management of vaccine-induced thrombotic thrombocytopenia, to provide a concise and comprehensive update.
摘要：
新型冠状病毒大流行对全球医疗保健系统和经济造成了损害。安全预防措施,随着疫苗接种，是最有效的预防措施。针对COVID-19的全球疫苗接种计划大大减少了死亡和病例数。然而,COVID-19疫苗接种后血栓事件和血小板减少症的发生率,即疫苗诱导的血栓性血小板减少症,引发了安全性问题.这导致了疫苗犹豫的因素。疫苗诱导的血栓性血小板减少症的确切机制尚不清楚。尽管与COVID-19疫苗接种相关的血栓形成的发生率很低，它仍然需要注意，尤其是老年人，吸烟者,和先前有合并症的人。本研究旨在回顾病理生理学，诊断,和疫苗诱导的血栓性血小板减少症的管理，提供简洁全面的更新。
